Genetic polymorphisms of p21 and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck

Carcinogenesis

Volumn 31, Issue 2, 2010, Pages 222-227

  Lei, Dapeng ^a,b,c   Sturgis, Erich M ^a   Liu, Zhensheng ^a   Zafereo, Mark E ^a,d   Wei, Qingyi ^a   Li, Guojun ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^b SHANDONG UNIVERSITY   (China)

^c SHANDONG UNIVERSITY   (China)

^d BAYLOR COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENOSINE; ANTINEOPLASTIC AGENT; CYTIDINE; PROTEIN P21; THYMIDINE; CDKN1A PROTEIN, HUMAN; CYCLIN DEPENDENT KINASE INHIBITOR 1A;

ADULT; ARTICLE; CANCER RADIOTHERAPY; CANCER RISK; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; HEAD AND NECK CARCINOMA; HEAD AND NECK SURGERY; HIGH RISK PATIENT; HOMOZYGOSITY; HUMAN; HYPOPHARYNX CARCINOMA; LARYNX CARCINOMA; MAJOR CLINICAL STUDY; MALE; MOUTH CARCINOMA; OROPHARYNX CARCINOMA; PRIORITY JOURNAL; RISK FACTOR; SECOND CANCER; SINGLE NUCLEOTIDE POLYMORPHISM; SQUAMOUS CELL CARCINOMA; WILD TYPE; COHORT ANALYSIS; GENETICS; HEAD AND NECK TUMOR; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SURVIVAL RATE;

CARCINOMA, SQUAMOUS CELL; COHORT STUDIES; CYCLIN-DEPENDENT KINASE INHIBITOR P21; FEMALE; GENOTYPE; HEAD AND NECK NEOPLASMS; HUMANS; MALE; MIDDLE AGED; NEOPLASMS, SECOND PRIMARY; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RISK FACTORS; SURVIVAL RATE;

EID: 77649200643     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgp279     Document Type: Article

References (54)

1. Sturgis, E.M. et al. (2007) Trends in head and neck cancer incidence in relation to smoking prevalence: an emerging epidemic of human papillomavirus-associated cancers? Cancer, 110, 1429-1435.
2. Jemal, A. et al. (2008) Cancer statistics, 2008. CA Cancer J. Clin., 58, 71-96.
3. Li, G. et al. (2006) The role of human papillomavirus in squamous carcinoma of the head and neck. Curr. Oncol. Rep., 8, 130-139.
4. Sturgis, E.M. et al. (1995) Second primary malignancies in the head and neck cancer patient. Ann. Otol. Rhinol. Laryngol., 104, 946-954.
5. Day, G.L. et al. (1992) Second primary tumors in patients with oral cancer. Cancer, 70, 14-19.
6. Yamamoto, E. et al. (2002) Site specific dependency of second primary cancer in early stage head and neck squamous cell carcinoma. Cancer, 94, 2007-2014.
7. Day, G.L. et al. (1994) Second cancers following oral and pharyngeal cancers: role of tobacco and alcohol. J. Natl Cancer Inst., 86, 131-137.
8. Do, K.A. et al. (2004) Longitudinal study of smoking patterns in relation to the development of smoking-related secondary primary tumors in patients with upper aerodigestive tract malignancies. Cancer, 101, 2837-2842.
9. León, X. et al. (2005) Metachronous second primary tumours in the aerodigestive tract in patients with early stage head and neck squamous cell carcinomas. Eur. Arch. Otorhinolaryngol., 262, 905-909.
10. Ng, A.K. et al. (2008) Second primary cancers: an overview. Hematol. Oncol. Clin. North. Am., 22, 271-289.
11. Gilbert, E.S. et al. (2003) Lung cancer after treatment for Hodgkin's disease: focus on radiation effects. Radiat. Res., 159, 161-173.
12. Wu, X. et al. (2009) Novel susceptibility loci for second primary tumors/recurrence in head and neck cancer patients: large-scale evaluation of genetic variants. Cancer Prev. Res., 2, 617-624.
13. Gal, T.J. et al. (2005) DNA repair gene polymorphisms and risk of second primary neoplasms and mortality in oral cancer patients. Laryngoscope, 115, 2221-2231.
14. Minard, C.G. et al. (2006) Evaluation of glutathione S-transferase polymorphisms and mutagen sensitivity as risk factors for the development of second primary tumors in patients previously diagnosed with early-stage head and neck cancer. Cancer, 106, 2636-2644.
15. Li, F. et al. (2009) p73 G4C14-to-A4T14 polymorphism and risk of second primary malignancy after index squamous cell carcinoma of head and neck. Int. J. Cancer, 125, 2660-2665.
16. Zafereo, M.E. et al. (2009) Glutathione S-transferase polymorphisms and risk of second primary malignancy after index squamous cell carcinoma of the head and neck. Cancer, Prev. Res., 2, 432-439.
17. Zafereo, M.E. et al. (2009) Nucleotide excision repair core gene polymorphisms and risk of second primary malignancy in patients with index squamous cell carcinoma of the head and neck. Carcinogenesis, 30, 997-1002.
18. Lloyd, R.V. et al. (1999) p27kip1: a multifunctional cyclin-dependent kinase inhibitor with prognostic significance in human cancers. Am. J. Pathol., 154, 313-323.
19. Cordon-Cardo, C. (1995) Mutations of cell cycle regulators. Biological and clinical implications for human neoplasia. Am.J. Pathol., 147, 545-560.
20. Hunter, T. et al. (1994) Cyclins and cancer. II: Cyclin D and CDK inhibitors come of age. Cell, 79, 573-582.
21. MacLachlan, T.K. et al. (1995) Cyclins, cyclin-dependent kinases and cdk inhibitors: implications in cell cycle control and cancer. Crit. Rev. Eukaryot. Gene Expr., 5, 127-156.
22. Xiong, Y. et al. (1993) p21 is a universal inhibitor of cyclin kinases. Nature, 366, 701-704.
23. el-Deiry, W.S. et al. (1993) WAF1, a potential mediator of p53 tumor suppression. Cell, 75, 817-825.
24. Lee, M.H. et al. (1995) Cloning of p57KIP2, a cyclin-dependent kinase inhibitor with unique domain structure and tissue distribution. Genes Dev., 9, 639-649.
25. Matsuoka, S. et al. (1995) P57KIP2, a structurally distinct member of the p21CIP1 Cdk inhibitor family, is a candidate tumor suppressor gene. Genes Dev., 9, 650-662.
26. Koufos, A. et al. (1989) Familial Wiedemann-Beckwith syndrome and a second Wilms tumor locus both map to 11p15.5. Am. J. Hum. Genet., 44, 711-719.
27. Hirai, H. et al. (1995) Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6. Mol. Cell. Biol., 15, 2672-2681.
28. Westfall, M.D. et al. (2003) The Delta Np63 alpha phosphoprotein binds the p21 and 14-3-3 sigma promoters in vivo and has transcriptional repressor activity that is reduced by Hay-Wells syndrome-derived mutations. Mol. Cell. Biol., 23, 2264-2276.
29. Komiya, T. et al. (1997) p21 expression as a predictor for favorable prognosis in squamous cell carcinoma of the lung. Clin. Cancer Res., 3, 1831-1835.
30. Zirbes, T.K. et al. (2000) Prognostic impact of p21/waf1/cip1 in colorectal cancer. Int. J. Cancer, 89, 14-18.
31. Lu, X. et al. (1998) Expression of p21WAF1/CIP1 in adenocarcinoma of the uterine cervix: a possible immunohistochemical marker of a favorable prognosis. Cancer, 82, 2409-2417.
32. Kapranos, N. et al. (2001) p53, p21 and p27 protein expression in head and neck cancer and their prognostic value. Anticancer Res., 21, 521-528.
33. Elledge, R.M. et al. (1998) Prognostic and predictive value of p53 and p21 in breast cancer. Breast Cancer Res. Treat., 52, 79-98.
34. Baekelandt, M. et al. (1999) Lack of independent prognostic significance of p21 and p27 expression in advanced ovarian cancer: an immunohistochemical study. Clin. Cancer Res., 5, 2848-2853.
35. Gohring, U.J. et al. (2001) p21(waf) correlates with DNA replication but not with prognosis in invasive breast cancer. J. Clin. Pathol., 54, 866-870.
36. Kaye, P.V. et al. (2000) Expression of p53 and p21waf1/cip1 in gastric carcinoma: lack of inter-relationship or correlation with prognosis. Eur. J. Surg. Oncol., 26, 39-43.
37. Haitel, A. et al. (2001) Expression of the cell cycle proteins P21, P27, and PRB in clear cell renal cell carcinoma and their prognostic significance. Urology, 58, 477-481.
38. Li, G. et al. (2005) Genetic polymorphisms of p21 are associated with risk of squamous cell carcinoma of the head and neck. Carcinogenesis, 26, 1596-1602.
39. Chen, K. et al. (2007) Polymorphic TP53BP1 and TP53 gene interactions associated with risk of squamous cell carcinoma of the head and neck. Clin. Cancer Res., 13, 4300-4305.
40. Zhen, S.L. et al. (2005) Polymorphisms of vitamin D receptor gene protect against risk of head and neck cancer. Pharmacogenet. Genomics., 15, 159-165.
41. Warren, S. et al. (1932) Multiple primary malignant tumors: a survey of the literature and statistical study. Am. J. Cancer, 51, 1358.
42. Powell, B.L. et al. (2002) Associations between common polymorphisms in TP53 and p21WAF1/Cip1 and phenotypic features of breast cancer. Carcinogenesis, 23, 311-315.
43. Choi, Y.Y. et al. (2008) Comprehensive assessment of P21 polymorphisms and lung cancer risk. J. Hum. Genet., 53, 87-95.
44. Knappskog, S. et al. (2007) Mutations and polymorphisms of the p21B transcript in breast cancer. Int. J. Cancer, 121, 908-910.
45. Santos, A.M. et al. (2006) TP53 and P21 polymorphisms: response to cisplatinum/paclitaxel-based chemotherapy in ovarian cancer. Biochem. Biophys. Res. Commun., 340, 256-262.
46. Chen, J. et al. (2008) Polymorphisms of p21 and p27 jointly contribute to an earlier age at diagnosis of pancreatic cancer. Cancer Lett., 272, 32-39.
47. Keshava, C. et al. (2002) Waf-1 (p21) and p53 polymorphisms in breast cancer. Cancer Epidemiol. Biomarkers. Prev., 11, 127-130.
48. Roh, J.W. et al. (2004) p53 and p21 genetic polymorphisms and susceptibility to endometrial cancer. Gynecol. Oncol., 93, 499-505.
49. Mousses, S. et al. (1995) Two variants of the CIP1/WAF1 gene occur together and are associated with human cancer. Hum. Mol. Genet., 4, 1089-1092.
50. Facher, E.A. et al. (1997) Association between human cancer and two polymorphisms occurring together in the p21Waf1/Cip1 cyclin-dependent kinase inhibitor gene. Cancer, 79, 2424-2429.
51. Hashibe, M. et al. (2005) Radiotherapy for oral cancer as a risk factor for second primary cancers. Cancer Lett., 220, 185-195.
52. Vokes, E.E. et al. (1993) Head and neck cancer. N. Engl. J. Med., 328, 184-194.
53. Argiris, A. et al. (2004) Competing causes of death and second primary tumors in patients with locoregionally advanced head and neck cancer treated with chemoradiotherapy. Clin. Cancer Res., 10, 1956-1962.
54. Dahlstrom, K.R. et al. (2003) Human papillomavirus type 16 infection and squamous cell carcinoma of the head and neck in never-smokers: a matched pair analysis. Clin. Cancer Res., 9, 2620-2626.